High market competition for innovative treatments and increasing pressure from payers and regulators are among the main drivers fueling the demand in comparator clinical trials, according to goBalto Head of Marketing Craig Morgan.
Morgan in a write up published on pharmaphorum says comparator trials, which are geared more toward the efficacy against a drug already on the market as opposed to utilizing a placebo, are used primarily for ethical reasons.
“Participants in many clinical trials are suffering from life-threatening illnesses and have enlisted in a study in order to gain access to effective treatment,” Morgan writes. “It would be unethical to give no treatment at all.”
Comparator trials also have the potential to deliver advantages in safety, convenience or cost effectiveness.
To read Morgan’s full report, click here.